Companies
Regeneron
leveraging human genetic databases to rapidly discover and commercialize novel targeted antibodies.
- Country
- United States
- Ticker
- REGN
antibodies
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $14.34 billion (2025-12-31) | investor.regeneron.com |
| Headcount | 15,410 employees (2025-12-31) | regeneron.com |
| Production site | Rensselaer, New York and Limerick, Ireland (2025-12-31) | investor.regeneron.com |
| Capacity | Approximately 100,000 liters (Rensselaer) and 120,000 liters (Limerick) of cell culture capacity (2025-12-31) | investor.regeneron.com |
| Certification | UK GMP Compliance Certificate for Rensselaer facility (2017-03-20) medium confidence | cms.mhra.gov.uk |
| Regulatory approval | Facilities approved by the FDA and other regulatory agencies to manufacture bulk drug materials and products (2025-12-31) | investor.regeneron.com |
| Funding | Sanofi is generally responsible for funding 80% to 100% of agreed-upon development expenses in their antibody collaboration (2025-12-31) | investor.regeneron.com |
Independent sources: cms.mhra.gov.uk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.